Molecules in the discovery phase are developed using the research platform ISP. The goal is to identify molecules that are able to advance into preclinical development.
The P001 research project comprises of a group molecules with focus on neurodegenerative disorders and aging. Drug candidates IRL942 & 1009 stem from the P001 research project, which is also continued in the discovery phase to support development of IRL942 & 1009 and to find new candidates with similar properties.
This research project comprises of a group of molecules with the potential to develop into drugs that replace levodopa as the treatment of newly diagnosed Parkinson’s disease.